EMD Serono
↗Boston Seaport District, MA, USA (200 Pier 4 Boulevard, Boston, MA)
EMD Serono is the U.S. and Canadian healthcare business of Merck KGaA, Darmstadt, Germany, a global science and technology company with over 350 years of history. The company specializes in biopharmaceutical research, development, and commercialization across therapeutic areas including neurology, endocrinology, oncology, and fertility treatments. EMD Serono is committed to developing innovative therapies for conditions including multiple sclerosis, myasthenia gravis, cancer, and infertility. With approximately 1,000 employees in the U.S., the company maintains fully integrated commercial, clinical, and research operations.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Biopharmaceuticals - Specialty Care
SIZE & FINANCIALS
Employees:1001-5000
Revenue:Multi-billion USD (part of Merck KGaA)
Founded:1971
Ownership:subsidiary
Status:operating
FUNDING
Stage:N/A (Subsidiary of public company)
STOCK
Exchange:Xetra (parent: Merck KGaA)
Ticker:MRK (parent company trades in Germany)
PIPELINE
Stage:Phase 1, 2, 3, and Commercial
Lead Drug Stage:Multiple Phase 2/3 programs
Modalities:Monoclonal Antibodies, Small Molecules, Antibody-Drug Conjugates (ADCs), Immunotherapies, Biologic Therapies
Active Trials:15
Trial Phases:Phase 1: 2 | Phase 2: 5 | Phase 3: 6 | Phase 4: 2
FDA Approvals:8
EMA Approvals:12
CORPORATE STRUCTURE
Parent Company:Merck KGaA, Darmstadt, Germany
Acquired By:Merck KGaA (2006-01-01)
Key Partnerships:Pfizer - Co-development of Bavencio for urothelial carcinoma, Hengrui Pharmaceuticals - Next-generation PARP1 inhibitor and ADC collaboration, Medisafe - Digital health tools for patient support, Rancho Biosciences - Data science advancement, MyHealthTeams - Patient support community for MS
COMPETITION
Position:Challenger
Competitors:Biogen (MS leader), Novartis (MS, oncology, autoimmune), Roche/Genentech (oncology, immunotherapy), Sanofi (MS, rare disease), Bristol Myers Squibb (oncology, immunotherapy), Merck & Co (oncology immunotherapies), Eli Lilly (fertility, oncology), Hummingbird Bioscience +2 more
LEADERSHIP
Key Executives:
Danny Schachter - President/CEO (Healthcare Division) - Member of Merck KGaA Executive Board
Rehan Verjee - President of EMD Serono, Global Head Innovative Medicine Franchises
Miguel Fernández Alcalde - Chief Operating Officer
Terri Stewart - SVP, Global Healthcare Government & Public Affairs
Kirk Taylor - SVP, North American Medical Affairs
Robert Truckenmiller - SVP, Market Access & Customer Solutions
Maria Rivas - SVP, Global Medical Affairs
Kate Cingolani - Head of Corporate Communications, North America
Stephanie Hayes Jameison - Head of US Advertising and Promotion & Interim Head Global Labeling N&I
Scientific Founders:Serono founding team (historical - now part of Merck)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of EMD Serono and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with EMD Serono. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.